finance.yahoo.com ·
journey medical corporation q1 2026 002526409
Topic context
This topic has been covered 359927 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedJourney Medical (a pharmaceutical company) reported strong Q1 2026 results driven by Emrosi, a dermatology product. The company secured broad PBM coverage, improving patient access and adherence. The commercial mechanism is company-specific: revenue growth from increased volume and refill rates, with margin impact from a $1.3M non-cash inventory write-down. No broader sector or commodity impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Journey Medical Corporation reported 21% YoY revenue growth in Q1 2026.
- Emrosi product scaling drove growth despite severe winter weather.
- Agreements with all three major PBM-owned GPOs covering ~85% of U.S. commercial lives.
- Refill-to-new-prescription ratio improved from 1:1 to 1.5:1.
- Company plans to add 5 sales professionals by early Q3 2026 and publish up to 3 journal articles.
Related stories
finance.yahoo.com
health tech q1 2026 earnings 215402558
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
economictimes.indiatimes.com
missiles over dubai rattle the gulfs billion dollar money machine dubai property uae deal ipo market
finance.yahoo.com
oncology institute q1 earnings call 050614985
economictimes.indiatimes.com